Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for vildagliptin (S09.003 inhibitor)

Summary Structure Literature Inhibits

(Topics flags: I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

    2019
  1. Balogh,M., Varga,B.K., Karadi,D.A., Riba,P., Puskar,Z., Kozsurek,M., Al-Khrasani,M. and Kiraly,K.
    Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, diprotin A and vildagliptin in rat inflammatory pain models following spinal administration
    Brain Res Bull (2019) 147, 78-85. PubMed  Europe PubMed DOI  I
  2. Borzi,A.M., Condorelli,G., Biondi,A., Basile,F., Vicari,E.S.D., Buscemi,C., Luca,S. and Vacante,M.
    Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment
    Arch Gerontol Geriatr (2019) 84, 103896-103896. PubMed  Europe PubMed DOI  I
  3. El-Naggar,A.R., Zaafar,D., Elyamany,M., Hassanin,S., Bassyouni,A. and Abdel-Latif,H.
    The role of vildagliptin in treating hypertension through modulating serum VEGF in diabetic hypertensive patients
    J Cardiovasc Pharmacol Ther (2019) 24, 254-261. PubMed  Europe PubMed DOI  I
  4. Jang,J.H., Janker,F., De Meester,I., Arni,S., Borgeaud,N., Yamada,Y., Gil Bazo,I., Weder,W. and Jungraithmayr,W.
    The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity
    Carcinogenesis (2019) 40, 324-334. PubMed  Europe PubMed DOI  I
  5. Mizuno,K., Takeuchi,K., Umehara,K. and Nakajima,M.
    Identification of novel metabolites of vildagliptin in rats: thiazoline-containing thiol adducts formed via cysteine or glutathione conjugation
    Drug Metab Dispos (2019) 47, 809-817. PubMed  Europe PubMed DOI  I
  6. Nakajima,Y., Ito,S., Asakura,M., Min,K.D., Fu,H.Y., Imazu,M., Hitsumoto,T., Takahama,H., Shindo,K., Fukuda,H., Yamazaki,S., Asanuma,H. and Kitakaze,M.
    A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats
    J Mol Cell Cardiol (2019) 129, 257-265. PubMed  Europe PubMed DOI  I
    7. 2018
  7. Mizuno,K., Takeuchi,K., Umehara,K. and Nakajima,M.
    Identification of a novel metabolite of vildagliptin in humans: cysteine targets the nitrile moiety to form a thiazoline ring
    Biochem Pharmacol (2018) 156, 312-321. PubMed  Europe PubMed DOI  I
    8. 2017
  8. Asakura,M., Fukami,T., Nakajima,M., Fujii,H., Atsuda,K., Itoh,T. and Fujiwara,R.
    Hepatic dipeptidyl peptidase-4 controls pharmacokinetics of vildagliptin in vivo
    Drug Metab Dispos (2017) 45, 237-245. PubMed  Europe PubMed DOI  I
  9. Del Prato,S.
    Ten years of vildagliptin
    Eur Endocrinol (2017) 13, 54-55. PubMed  Europe PubMed DOI  PMC  EPMC  I
  10. Foley,J.E. and Ahren,B.
    The vildagliptin experience - 25 years since the initiation of the Novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration
    Eur Endocrinol (2017) 13, 56-61. PubMed  Europe PubMed DOI  PMC  EPMC  I
  11. Strain,W.D. and Paldanius,P.M.
    Dipeptidyl peptidase-4 inhibitor development and post-authorisation programme for vildagliptin - clinical evidence for optimised management of chronic diseases beyond type 2 diabetes
    Eur Endocrinol (2017) 13, 62-67. PubMed  Europe PubMed DOI  PMC  EPMC  I
  12. Trevisan,R.
    The role of vildagliptin in the therapy of type 2 diabetic patients with renal dysfunction
    Diabetes Ther (2017) 8, 1215-1226. PubMed  Europe PubMed DOI  I
    13. 2016
  13. Tsuboi,K., Mizukami,H., Inaba,W., Baba,M. and Yagihashi,S.
    The dipeptidyl peptidase IV inhibitor vildagliptin suppresses development of neuropathy in diabetic rodents: effects on peripheral sensory nerve function, structure and molecular changes
    J Neurochem (2016) 136, 859-870. PubMed  Europe PubMed DOI  I
    14. 2015
  14. Asakura,M., Fujii,H., Atsuda,K., Itoh,T. and Fujiwara,R.
    Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver
    Drug Metab Dispos (2015) 43, 477-484. PubMed  Europe PubMed DOI  I
  15. Ateyya,H.
    Amelioration of cyclosporine induced nephrotoxicity by dipeptidyl peptidase inhibitor vildagliptin
    Int Immunopharmacol (2015) 28, 571-577. PubMed  Europe PubMed DOI  I
  16. Gilibili,R.R., Bhamidipati,R.K., Mullangi,R. and Srinivas,N.R.
    Retrospective and prospective human intravenous and oral pharmacokinetic projection of dipeptidyl peptidase-IV inhibitors using simple allometric principles - case studies of ABT-279, ABT-341, alogliptin, carmegliptin, sitagliptin and vildagliptin
    J Pharm Pharm Sci (2015) 18, 434-448. PubMed  Europe PubMed  I
  17. Inthachai,T., Lekawanvijit,S., Kumfu,S., Apaijai,N., Pongkan,W., Chattipakorn,S.C. and Chattipakorn,N.
    Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction
    Exp Physiol (2015) 100, 667-679. PubMed  Europe PubMed DOI  I
  18. Ito,D., Inoue,K., Kaneko,K., Yanagisawa,M., Sumita,T., Ikegami,Y., Awata,T., Ishida,H., Katayama,S. and Inukai,K.
    The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects
    J Clin Med Res (2015) 7, 303-307. PubMed  Europe PubMed DOI  PMC  EPMC  I
  19. Kothny,W., Lukashevich,V., Foley,J.E., Rendell,M.S. and Schweizer,A.
    Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
    Diabetologia (2015) 58, 2020-2026. PubMed  Europe PubMed DOI  I
  20. Malmgren,S. and Ahren,B.
    DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice
    Diabetologia (2015) 58, 1091-1099. PubMed  Europe PubMed DOI  I
  21. McInnes,G., Evans,M., Del Prato,S., Stumvoll,M., Schweizer,A., Lukashevich,V., Shao,Q. and Kothny,W.
    Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients
    Diabetes Obes Metab (2015) 17, 1085-1092. PubMed  Europe PubMed DOI  I
  22. Mera,J., Okada,E., Okuda,M., Ota,T., Sibata,S. and Uchida,S.
    Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis
    J Diabetes Metab Disord (2015) 14, 83-83. PubMed  Europe PubMed DOI  PMC  EPMC  I
  23. Scheen,A.J.
    Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
    Expert Opin Drug Saf (2015) 14, 505-524. PubMed  Europe PubMed DOI  I
  24. Takeshita,Y., Takamura,T., Kita,Y., Otoda,T., Kato,K., Wakakuri,H., Yamada,M., Misu,H., Matsushima,Y. and Kaneko,S.
    Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: a randomized, parallel-group study
    J Diabetes Investig (2015) 6, 192-200. PubMed  Europe PubMed DOI  PMC  EPMC  I
  25. Tani,S., Takahashi,A., Nagao,K. and Hirayama,A.
    Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus
    Am J Cardiol (2015) 115, 454-460. PubMed  Europe PubMed DOI  I
  26. Wu,Y.J., Guo,X., Li,C.J., Li,D.Q., Zhang,J., Yang,Y., Kong,Y., Guo,H., Liu,D.M. and Chen,L.M.
    Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice
    Metabolism (2015) 64, 226-235. PubMed  Europe PubMed DOI  I
    27. 2014
  27. Keating,G.M.
    Vildagliptin: a review of its use in type 2 diabetes mellitus
    Drugs (2014) 74, 587-610. PubMed  Europe PubMed DOI  I
  28. Renna,N.F., Diez,E.A. and Miatello,R.M.
    Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model
    PLoS ONE (2014) 9, e106563-e106563. PubMed  Europe PubMed DOI  PMC  EPMC  I
  29. Stein,S.A., Lamos,E.M. and Davis,S.N.
    Vildagliptin , a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
    Expert Opin Drug Metab Toxicol (2014) 10, 599-608. PubMed  Europe PubMed DOI  I
    30. 2013
  30. Chakraborty,S., Rendon-Ramirez,A., Asgeirsson,B., Dutta,M., Ghosh,A.S., Oda,M., Venkatramani,R., Rao,B.J., Dandekar,A.M. and Goni,F.M.
    The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
    F1000 Res (2013) 2, 286-286. PubMed  Europe PubMed DOI  I
  31. Kothny,W., Foley,J., Kozlovski,P., Shao,Q., Gallwitz,B. and Lukashevich,V.
    Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
    Diabetes Obes Metab (2013) 15, 252-257. PubMed  Europe PubMed DOI  I
  32. Nabeno,M., Akahoshi,F., Kishida,H., Miyaguchi,I., Tanaka,Y., Ishii,S. and Kadowaki,T.
    A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
    Biochem Biophys Res Commun (2013) 434, 191-196. PubMed  Europe PubMed DOI  I
  33. Pintana,H., Apaijai,N., Chattipakorn,N. and Chattipakorn,S.C.
    DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats
    J Endocrinol (2013) 218, 1-11. PubMed  Europe PubMed DOI  I
  34. Pipatpiboon,N., Pintana,H., Pratchayasakul,W., Chattipakorn,N. and Chattipakorn,S.C.
    DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption
    Eur J Neurosci (2013) 37, 839-849. PubMed  Europe PubMed DOI  I
  35. Spagnuolo,P.A., Hurren,R., Gronda,M., Maclean,N., Datti,A., Basheer,A., Lin,F.H., Wang,X., Wrana,J. and Schimmer,A.D.
    Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity
    Leukemia (2013) 27, 1236-1244. PubMed  Europe PubMed DOI  I
  36. Tatosian,D.A., Guo,Y., Schaeffer,A.K., Gaibu,N., Popa,S., Stoch,A., Langdon,R.B. and Kauh,E.A.
    Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
    Diabetes Ther (2013) 4, 431-442. PubMed  Europe PubMed DOI  I
  37. Teramachi,H., Ohta,H., Tachi,T., Toyoshima,M., Mizui,T., Goto,C. and Tsuchiya,T.
    Pharmacoeconomic analysis of DPP-4 inhibitors
    Pharmazie (2013) 68, 909-915. PubMed  Europe PubMed DOI  I
    38. 2012
  38. Akarte,A.S., Srinivasan,B.P. and Gandhi,S.
    Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin
    Eur J Pharm Sci (2012) 45, 546-551. PubMed  Europe PubMed DOI  I
  39. Apaijai,N., Pintana,H., Chattipakorn,S.C. and Chattipakorn,N.
    Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet
    Endocrinology (2012) 153, 3878-3885. PubMed  Europe PubMed DOI  I
  40. Barden,A.T., Salamon,B., Schapoval,E.E. and Steppe,M.
    Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product
    J Chromatogr Sci (2012) 50, 426-432. PubMed  Europe PubMed DOI  I
  41. Cai,L., Cai,Y., Lu,Z.J., Zhang,Y. and Liu,P.
    The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
    J Clin Pharm Ther (2012) 37, 386-398. PubMed  Europe PubMed DOI  I
  42. Dejager,S., Schweizer,A. and Foley,J.E.
    Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
    Vasc Health Risk Manag (2012) 8, 339-348. PubMed  Europe PubMed DOI  PMC  EPMC  I
  43. Derosa,G. and Maffioli,P.
    Dipeptidyl peptidase-4 inhibitors: 3 years of experience
    Diabetes Technol Ther (2012) 14, 350-364. PubMed  Europe PubMed DOI  I
  44. Gibbs,J.P., Fredrickson,J., Barbee,T., Correa,I., Smith,B., Lin,S.L. and Gibbs,M.A.
    Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results
    J Clin Pharmacol (2012) 52, 1494-1505. PubMed  Europe PubMed DOI  I
  45. Golightly,L.K., Drayna,C.C. and McDermott,M.T.
    Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
    Clin Pharmacokinet (2012) 51, 501-514. PubMed  Europe PubMed DOI  I
  46. He,Y.L.
    Clinical pharmacokinetics and pharmacodynamics of vildagliptin
    Clin Pharmacokinet (2012) 51, 147-162. PubMed  Europe PubMed DOI  I
  47. He,Y.L., Ito,H., Yamaguchi,M., Terao,S., Shimada,S., Irie,S. and Sekiguchi,K.
    Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes
    Int J Clin Pharmacol Ther (2012) 50, 237-247. PubMed  Europe PubMed DOI  I
  48. Kothny,W., Shao,Q., Groop,P.H. and Lukashevich,V.
    One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment
    Diabetes Obes Metab (2012) 14, 1032-1039. PubMed  Europe PubMed DOI  I
  49. Landersdorfer,C.B., He,Y.L. and Jusko,W.J.
    Mechanism-based population pharmacokinetic modelling in diabetes: Vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV
    Br J Clin Pharmacol (2012) 73, 391-401. PubMed  Europe PubMed DOI  I
  50. Liu,W.J., Xie,S.H., Liu,Y.N., Kim,W., Jin,H.Y., Park,S.K., Shao,Y.M. and Park,T.S.
    Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats
    J Pharmacol Exp Ther (2012) 340, 248-255. PubMed  Europe PubMed DOI  I
  51. Monami,M., Lamanna,C., Desideri,C.M. and Mannucci,E.
    DPP-4 Inhibitors and lipids: systematic review and meta-analysis
    Adv Ther (2012) 29, 14-25. PubMed  Europe PubMed DOI  I
  52. Sato,K., Nakamura,A., Shirakawa,J., Muraoka,T., Togashi,Y., Shinoda,K., Orime,K., Kubota,N., Kadowaki,T. and Terauchi,Y.
    Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and beta-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet
    Endocrinology (2012) 153, 1093-1102. PubMed  Europe PubMed DOI  I
  53. Schweizer,A., Dejager,S. and Foley,J.E.
    Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin
    Diabetes Ther (2012) 3, 8-8. PubMed  Europe PubMed DOI  I
    54. 2011
  54. Ahren,B., Schweizer,A., Dejager,S., Villhauer,E.B., Dunning,B.E. and Foley,J.E.
    Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
    Diabetes Obes Metab (2011) 13, 775-783. PubMed  Europe PubMed DOI  I
  55. Chambel,P., Marcelino,M., Domingues,A., Vilar,H., Lopes,L., Paradinha,M., Lopes,M.S., Carvalho,R., Santos,V. and Jacome De Castro,J.
    [Characterization of patients with type 2 diabetes treated with vildagliptin]
    Acta Med Port (2011) 24, 555-560. PubMed  Europe PubMed  I
  56. Dejager,S. and Schweizer,A.
    Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management
    Diabetes Ther (2011) 2, 51-66. PubMed  Europe PubMed DOI  PMC  EPMC  I
  57. Gupta,V. and Kalra,S.
    Choosing a gliptin
    Indian J Endocrinol Metab (2011) 15, 298-308. PubMed  Europe PubMed DOI  PMC  EPMC  I
  58. He,Y.L., Zhang,Y., Serra,D., Wang,Y., Ligueros-Saylan,M. and Dole,W.P.
    Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers
    Curr Med Res Opin (2011) 27, 1453-1463. PubMed  Europe PubMed DOI  I
  59. Ito,M., Abe,M., Okada,K., Sasaki,H., Maruyama,N., Tsuchida,M., Higuchi,T., Kikuchi,F. and Soma,M.
    The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
    Endocr J (2011) 58, 979-987. PubMed  Europe PubMed  I
  60. Jermendy,G.
    [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]
    Orv Hetil (2011) 152, 1471-1476. PubMed  Europe PubMed DOI  V  I
  61. Kalra,S.
    Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes
    J Assoc Physicians India (2011) 59, 237-245. PubMed  Europe PubMed  I
  62. Kalra,S., Unnikrishnan,A.G., Agrawal,N. and Singh,A.K.
    Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications
    Recent Pat Endocr Metab Immune Drug Discov (2011) 5, 197-202. PubMed  Europe PubMed DOI  I
  63. Kiraly,K., Lambeir,A.M., Szalai,J., Szentirmay,A., Luyten,W., Barna,I., Puskar,Z., Kozsurek,M. and Ronai,A.Z.
    The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord
    Eur J Pharmacol (2011) 650, 195-199. PubMed  Europe PubMed DOI  I
  64. Matsui,T., Nishino,Y., Takeuchi,M. and Yamagishi,S.
    Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis
    Pharmacol Res (2011) 63, 383-388. PubMed  Europe PubMed DOI  I
  65. Richard,K.R., Shelburne,J.S. and Kirk,J.K.
    Tolerability of dipeptidyl peptidase-4 inhibitors: a review
    Clin Ther (2011) 33, 1609-1629. PubMed  Europe PubMed DOI  V  I
  66. Sehra,D. and Sehra,S.
    Emerging role of DPP-4 inhibitor vildagliptin in the management of type-2 diabetes
    J Assoc Physicians India (2011) 59, 744-744. PubMed  Europe PubMed  I
  67. Signorovitch,J.E., Wu,E.Q., Swallow,E., Kantor,E., Fan,L. and Gruenberger,J.B.
    Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials
    Clin Drug Investig (2011) 31, 665-674. PubMed  Europe PubMed DOI  I
  68. Stamataros,G. and Schneider,S.H.
    Vildagliptin in the treatment of type 2 diabetes mellitus
    Expert Opin Pharmacother (2011) 12, 1967-1973. PubMed  Europe PubMed DOI  I
  69. Tomioka,Y.
    Clinical experience of a selective dipeptidyl peptidase IV inhibitor, vildagliptin
    Ther Res (2011) 32, 841-849.  I
  70. van Poppel,P.C., Netea,M.G., Smits,P. and Tack,C.J.
    Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes
    Diabetes Care (2011) 34, 2072-2077. PubMed  Europe PubMed DOI  I
  71. Yin,M., Sillje,H.H., Meissner,M., van Gilst,W.H. and de Boer,R.A.
    Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
    Cardiovasc Diabetol (2011) 10, 85-85. PubMed  Europe PubMed DOI  I
    72. 2010
  72. Gerich,J.
    DPP-4 inhibitors: What may be the clinical differentiators?
    Diabetes Res Clin Pract (2010) 90, 131-140. PubMed  Europe PubMed DOI  V  I
  73. Haidinger,M., Werzowa,J., Voigt,H.C., Pleiner,J., Stemer,G., Hecking,M., Doller,D., Horl,W.H., Weichhart,T. and Saemann,M.D.
    A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation
    Trials (2010) 11, 91-91. PubMed  Europe PubMed DOI  I
  74. Halimi,S., Raccah,D., Schweizer,A. and Dejager,S.
    Role of vildagliptin in managing type 2 diabetes mellitus in the elderly
    Curr Med Res Opin (2010) 26, 1647-1656. PubMed  Europe PubMed DOI  I
  75. Ito,H., Wajima,T., Yamaguchi,M., Mimori,N. and Sekiguchi,K.
    Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin
    Nihon Yakurigaku Zasshi (2010) 136, 299-308. DOI  I
  76. Wang,X., Zhang,D., Xu,W., Liu,H. and Wang,W.
    Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats
    Xenobiotica (2010) 40, 707-712. PubMed  Europe PubMed DOI  I
    77. 2009
  77. D'Alessio,D.A., Denney,A.M., Hermiller,L.M., Prigeon,R.L., Martin,J.M., Tharp,W.G., Saylan,M.L., He,Y., Dunning,B.E., Foley,J.E. and Pratley,R.E.
    Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes
    J Clin Endocrinol Metab (2009) 94, 81-88. PubMed  Europe PubMed DOI  PMC  EPMC  I
  78. Dalla Man,C., Bock,G., Giesler,P.D., Serra,D.B., Ligueros Saylan,M., Foley,J.E., Camilleri,M., Toffolo,G., Cobelli,C., Rizza,R.A. and Vella,A.
    Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes
    Diabetes Care (2009) 32, 14-18. PubMed  Europe PubMed DOI  PMC  EPMC  I
  79. He,H., Tran,P., Yin,H., Smith,H., Batard,Y., Wang,L., Einolf,H., Gu,H., Mangold,J.B., Fischer,V. and Howard,D.
    Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
    Drug Metab Dispos (2009) 37, 536-544. PubMed  Europe PubMed DOI  I
  80. He,H., Tran,P., Yin,H., Smith,H., Flood,D., Kramp,R., Filipeck,R., Fischer,V. and Howard,D.
    Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs
    Drug Metab Dispos (2009) 37, 545-554. PubMed  Europe PubMed DOI  I
  81. Jin,H.Y., Liu,W.J., Park,J.H., Baek,H.S. and Park,T.S.
    Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats
    Arch Med Res (2009) 40, 536-544. PubMed  Europe PubMed DOI  I
  82. Johnson,J.T., Golden,K.L. and Braceras,R.
    An update of recent trials with vildagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    J Pharm Technol (2009) 25, 235-243.  I
  83. Kintscher,U.
    Dipeptidyl peptidase-4 (DPP-4) lnhibtors: a new oral alternative [Dipeptidyl-Peptidase-4 (DPP-4)-lnhibitoren: neue orale Alternative]
    Diabetes Stoffwechsel Herz (2009) 18, 169-175.  I
  84. Matsuyama-Yokono,A., Tahara,A., Nakano,R., Someya,Y., Shiraki,K., Hayakawa,M. and Shibasaki,M.
    Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice
    Metabolism (2009) 58, 379-386. PubMed  Europe PubMed DOI  I
  85. Smushkin,G. and Vella,A.
    Inhibition of dipeptidyl peptidase-4: the mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
    Diabetes Metab Syndr Obes (2009) 2, 83-90. PubMed  Europe PubMed  I
  86. Thornberry,N.A. and Gallwitz,B.
    Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
    Best Pract Res Clin Endocrinol Metab (2009) 23, 479-486. PubMed  Europe PubMed DOI  I
    87. 2008
  87. Croxtall,J.D. and Keam,S.J.
    Vildagliptin: a review of its use in the management of type 2 diabetes mellitus
    Drugs (2008) 68, 2387-2409. PubMed  Europe PubMed  I
  88. Pei,Z.
    From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents
    Curr Opin Drug Discov Devel (2008) 11, 512-532. PubMed  Europe PubMed  I
  89. Singh,S.K., Manne,N. and Pal,M.
    Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: a key intermediate for dipeptidyl peptidase IV inhibitors
    Beilstein J Org Chem (2008) 4, 20-20. PubMed  Europe PubMed DOI  PMC  EPMC  I
  90. Wani,J.H., John-Kalarickal,J. and Fonseca,V.A.
    Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review
    Cardiol Clin (2008) 26, 639-648. PubMed  Europe PubMed DOI  V  I
    91. 2007
  91. Balas,B., Baig,M.R., Watson,C., Dunning,B.E., Ligueros-Saylan,M., Wang,Y., He,Y.L., Darland,C., Holst,J.J., Deacon,C.F., Cusi,K., Mari,A., Foley,J.E. and Defronzo,R.A.
    The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
    J Clin Endocrinol Metab (2007) 92, 1249-1255. PubMed  Europe PubMed DOI  I
  92. Bosi,E., Camisasca,R.P., Collober,C., Rochotte,E. and Garber,A.J.
    Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled With metformin
    Diabetes Care (2007) 30, 890-895. PubMed  Europe PubMed DOI  I
  93. El-Ouaghlidi,A., Rehring,E., Holst,J.J., Schweizer,A., Foley,J., Holmes,D. and Nauck,M.A.
    The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
    J Clin Endocrinol Metab (2007) 92, 4165-4171. PubMed  Europe PubMed DOI  I
  94. Fonseca,V., Schweizer,A., Albrecht,D., Baron,M.A., Chang,I. and Dejager,S.
    Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    Diabetologia (2007) 50, 1148-1155. PubMed  Europe PubMed DOI  I
  95. He,Y.L., Sabo,R., Campestrini,J., Wang,Y., Ligueros-Saylan,M., Lasseter,K.C., Dilzer,S.C., Howard,D. and Dole,W.P.
    The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin
    Eur J Clin Pharmacol (2007) 63, 677-686. PubMed  Europe PubMed DOI  I
  96. He,Y.L., Serra,D., Wang,Y., Campestrini,J., Riviere,G.J., Deacon,C.F., Holst,J.J., Schwartz,S., Nielsen,J.C. and Ligueros-Saylan,M.
    Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
    Clin Pharmacokinet (2007) 46, 577-588. PubMed  Europe PubMed DOI  I
  97. Lauster,C.D., McKaveney,T.P. and Muench,S.V.
    Vildagliptin: a novel oral therapy for type 2 diabetes mellitus
    Am J Health Syst Pharm (2007) 64, 1265-1273. PubMed  Europe PubMed DOI  I
  98. Panina,G.
    The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond
    Diabetes Obes Metab (2007) 9 Suppl 1, 32-39. PubMed  Europe PubMed DOI  I
  99. Peters,J.U.
    11 Years of cyanopyrrolidines as DPP-IV inhibitors
    Curr Top Med Chem (2007) 7, 579-595. PubMed  Europe PubMed DOI  I
    100. 2006
  100. Ahren,B.
    Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
    Expert Opin Investig Drugs (2006) 15, 431-442. PubMed  Europe PubMed DOI  I
  101. Henness,S. and Keam,S.J.
    Vildagliptin
    Drugs (2006) 66, 1989-2001. PubMed  Europe PubMed DOI  I
  102. Pratley,R.E., Jauffret-Kamel,S., Galbreath,E. and Holmes,D.
    Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
    Horm Metab Res (2006) 38, 423-428. PubMed  Europe PubMed DOI  I
  103. Pratley,R.E., Salsali,A. and Matfin,G.
    Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes
    Br J Diabetes Vasc Dis (2006) 6, 150-156.  I
  104. Ristic,S. and Bates,P.C.
    Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes
    Drugs Today (Barc) (2006) 42, 519-531. PubMed  Europe PubMed DOI  I
  105. Schlesselman,L.S.
    Vildagliptin: A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes
    Formulary (2006) 41, 494-500.  I
    106. 2005
  106. Ahren,B., Pacini,G., Foley,J.E. and Schweizer,A.
    Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1year
    Diabetes Care (2005) 28, 1936-1940. PubMed  Europe PubMed DOI  I
  107. [YEAR:1-7-2005]Brandt,I., Joossens,J., Chen,X., Maes,M.B., Scharpe,S., De Meester,I. and Lambeir,A.M.
    Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile)
    Biochem Pharmacol (1-7-2005) 70, 134-143. PubMed  Europe PubMed DOI  I
  108. [YEAR:18-7-2005]Burkey,B.F., Li,X., Bolognese,L., Balkan,B., Mone,M., Russell,M., Hughes,T.E. and Wang,P.R.
    Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats
    J Pharmacol Exp Ther (18-7-2005) 315, 688-695. PubMed  Europe PubMed DOI  I
  109. [YEAR:10-5-2005]Mari,A., Sallas,W.M., He,Y.L., Watson,C., Ligueros-Saylan,M., Dunning,B.E., Deacon,C.F., Holst,J.J. and Foley,J.E.
    Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
    J Clin Endocrinol Metab (10-5-2005) 90, 4888-4894. PubMed  Europe PubMed DOI  I
  110. Ristic,S., Byiers,S., Foley,J. and Holmes,D.
    Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
    Diabetes Obes Metab (2005) 7, 692-698. PubMed  Europe PubMed DOI  I
    111. 2004
  111. Ahren,B., Gomis,R., Standl,E., Mills,D. and Schweizer,A.
    Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    Diabetes Care (2004) 27, 2874-2880. PubMed  Europe PubMed DOI  I
  112. Ahren,B., Landin-Olsson,M., Jansson,P.A., Svensson,M., Holmes,D. and Schweizer,A.
    Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
    J Clin Endocrinol Metab (2004) 89, 2078-2084. PubMed  Europe PubMed DOI  I
  113. McIntyre,J.A. and Castaner,J.
    Vildagliptin. Agent for type 2 diabetes, dipeptidyl-peptidase IV inhibitor
    Drugs Future (2004) 29, 887-891.  I
    114. 2003
  114. [YEAR:19-6-2003]Villhauer,E.B., Brinkman,J.A., Naderi,G.B., Burkey,B.F., Dunning,B.E., Prasad,K., Mangold,B.L., Russell,M.E. and Hughes,T.E.
    1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
    J Med Chem (19-6-2003) 46, 2774-2789. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2026 EBI
Terms of use